Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 1999

View Archived Issues

Effects of NOS gene therapy on atherogenic markers in cholesterol-fed rabbits

ID Biomedical and Sybron subsidiary sign diagnostics licensing agreements

Sibia Neurosciences licenses transcription-based assay technology to AHP

Cangene seeks approval of VZIG in Canada

Maxim updates Maxamine clinical trial program

Bio-Rad to acquire Pasteur Sanofi Diagnostics

Ritonavir found to be more potent inhibitor of P-glycoprotein than SDZ-PSC-833

Pherin and Janssen enter agreement for anxiolytic products

Health Canada approves Betaseron for treatment of SPMS

NeuroVir's G-207 is a promising treatment for a lethal disease: glioblastoma

New sigma-receptor ligands claimed by Mitsubishi for CNS, GI and cardiovascular disorders

Teijin presents new series of chemokine antagonists

Competitive inhibitors of trypsin-like proteases in development at AstraZeneca

Benzimidazoles for acute and chronic inflammatory diseases patented by Taiho

Anticoagulants acting specifically on factor Xa synthesized at Teijin

Gruenenthal designs new analgesics

Fenretinide: a promising retinoid compound with a novel mechanism of action

GYKI-16638: structure and electrophysiological properties presented at scientific meeting

Two more European countries permit phase II studies of resiniferatoxin

Newly synthesized torasemide derivative exhibits profile of potent and specific TxA2 antagonist

European Congress of Pharmacology presentation for novel 5-HT1B/1D receptor ligand NAS-438

Egis reports results from pharmacological comparison of EGIS-7625 and methysergide

Plaferone in the treatment of asthma and respiratory infections

The Liposome Company now seeks approval for Evacet in Canada

E-047/1: Ebewe reports pharmacological profile and promising early clinical results

Positive results from phase II psoriasis study of hu1124 presented at dermatology meeting

Development candidates selected from series of highly potent ellipticine/olivacine derivatives

Combination vaccine more effective against Lyme disease

Boston Biomedica awarded SBIR grant to develop natural product-based HIV drug candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...